Comparative Pharmacology
Head-to-head clinical analysis: AUREOMYCIN versus RONDOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUREOMYCIN versus RONDOMYCIN.
AUREOMYCIN vs RONDOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking aminoacyl-tRNA binding.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours; or 10-20 mg/kg/day intravenously divided every 12 hours
150 mg orally twice daily or 300 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 8–12 hours (prolonged in renal impairment; may extend to 20–30 hours in anuria)
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may extend to 20-30 hours in severe renal impairment.
Renal (70% unchanged), biliary/fecal (30% as metabolites and unchanged drug)
Renal (40-50% unchanged), biliary/fecal (10-20% as metabolites and unchanged drug). Approximately 30% undergoes enterohepatic circulation.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic